Table 2.
Proportions of FA composition in plasma phospholipids and estimated desaurase activities between HF patients with MetS and without MetS
| HF without MetS (n = 59) | HF with MetS (n = 26) | p | |
|---|---|---|---|
| 12:0 lauric acid | 0.24 ± 0.15 | 0.18 ± 0.09 | <0.05 |
| 14:0 myristic acid | 0.7 ± 0.17 | 0.66 ± 0.19 | ns |
| 16:0 palmitic acid | 27.45 ± 2.93 | 27.85 ± 2.28 | ns |
| 16:1 palmitoleic acid | 0.77 ± 0.23 | 0.83 ± 0.26 | ns |
| 18:0 stearic acid | 14.99 ± 1.94 | 14.49 ± 1.69 | ns |
| 18:1 ω9 oleic acid | 8.06 ± 1.45 | 8.04 ± 1.34 | ns |
| 18:1 t ω9 elaidic acid | 2.24 ± 0.58 | 2.15 ± 0.68 | ns |
| 18:2 ω6 linoleic acid | 14.11 ± 2.79 | 13.11 ± 2.77 | ns |
| 18:2 tt linolelaidic acid | 0.69 ± 0.3 | 0.66 ± 0.25 | ns |
| 18:3 ω6 γ-linolenic acid | 0.27 ± 0.12 | 0.26 ± 0.05 | ns |
| 18:3 ω3 α-linolenic acid | 0.59 ± 0.26 | 0.66 ± 0.25 | ns |
| 20:0 arachidic acid | 0.97 ± 0.23 | 1.0 ± 0.33 | ns |
| 20:1 ω9 gondoic acid(cis-11-eicosenoic acid) | 0.39 ± 0.15 | 0.35 ± 0.1 | ns |
| 20:2 cis-11,14-eicosadienoic acid | 1.24 ± 0.77 | 1.15 ± 0.27 | ns |
| 20:3 ω6 dihimo-γ-linolenic acid | 2.5 ± 0.62 | 2.9 ± 0.74 | <0.05 |
| 20:3 ω3 5-8-11-eicosatrienoic acid | 0.45 ± 0.25 | 0.38 ± 0.14 | ns |
| 20:4 ω6 arachidonic acid | 7.02 ± 1.61 | 7.04 ± 1.47 | ns |
| 20:5 ω3 EPA | 2.7 ± 1.2 | 3.26 ± 1.28 | ns |
| 22:0 behenic acid | 1.88 ± 0.5 | 1.91 ± 0.38 | ns |
| 22:1 erucic acid | 0.6 ± 0.21 | 0.54 ± 0.16 | ns |
| 22:2 docosadienoic acid | 0.37 ± 0.27 | 0.33 ± 0.12 | ns |
| 24:0 lignoceric acid | 1.96 ± 0.72 | 1.9 ± 0.64 | ns |
| 22:6 ω3 DHA | 8.26 ± 2.17 | 8.88 ± 1.81 | ns |
| SCD16 (16:1n-7/16:0) | 0.028 ± 0.009 | 0.03 ± 0.009 | ns |
| SCD18 (18:1n-9/18:0) | 0.54 ± 0.12 | 0.56 ± 0.11 | ns |
| D6D (20:3n-6/18:2n-6) | 0.18 ± 0.06 | 0.23 ± 0.09 | <0.01 |
| D5D (20:4n-6/20:3n-6) | 2.96 ± 0.98 | 2.53 ± 0.63 | <0.05 |
Mean ± SD. Expressed as percentage of total fatty acids.